Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
April 03, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae Data to be Presented in Oral Session at...
Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Presentation at ECCMID 2018
April 23, 2018 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom and CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces it highlighted the discovery of new mechanism antibiotic...
ECCMID Presentation to Demonstrate Revolutionary Breakthrough in Malaria Detection
April 17, 2017 05:30 ET
|
Meridian Bioscience, Inc.
VIENNA, Austria, April 17, 2017 (GLOBE NEWSWIRE) -- Leading malaria researcher Tom van Gool’s presentation at the 27th European Congress for Clinical Microbiology and Infectious Diseases (ECCMID)...
Positive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential of Ridinilazole in the Treatment of C. difficile Infection
April 11, 2016 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, April 11, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit to Present Additional Data From Phase 2 CoDIFy Trial Showing Ridinilazole’s Statistical Superiority Over Vancomycin in Sustained Clinical Response was Driven by Marked Reduction in Recurrence of C. difficile Infection
March 29, 2016 09:25 ET
|
Summit Therapeutics plc
Data to be Presented at 26th ECCMID Conference, 11 April 2016 OXFORD, United Kingdom, March 29, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and...
Cempra Reports First Quarter 2015 Financial Results and Provides Corporate Update
April 30, 2015 16:04 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., April 30, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...